GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiRx Inc (ROCO:6580) » Definitions » Net Income Including Noncontrolling Interests

TaiRx (ROCO:6580) Net Income Including Noncontrolling Interests : NT$-138.84 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is TaiRx Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

TaiRx's Net Income Including Noncontrolling Interests for the six months ended in Dec. 2024 was NT$-67.00 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-138.84 Mil.

TaiRx Net Income Including Noncontrolling Interests Historical Data

The historical data trend for TaiRx's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TaiRx Net Income Including Noncontrolling Interests Chart

TaiRx Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -162.31 -127.46 -211.57 -212.29 -138.84

TaiRx Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -109.02 -100.36 -111.93 -71.84 -67.00

TaiRx Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-138.84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiRx Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of TaiRx's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

TaiRx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TaiRx Inc (ROCO:6580) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
ROCO:6461 ROCO:4169 ROCO:7808 ROCO:6892 TPE:6885 ROCO:4130 ROCO:6704 ROCO:7754 ROCO:6864 ROCO:6748 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
No. 66, Sanchong Road, 1st Floor, 6th Floor, Nangang District, Taipei, TWN, 11502
Website
https://www.trx.com.tw
TaiRx Inc is a pharmaceutical company based in Taiwan. It develops new drugs and improves current standard treatments to promptly find cures for diseases and fulfill unmet medical needs. The company focuses on new drug development for Asia and other markets.

TaiRx Headlines

No Headlines